Merck & Co Inc (BSP:MRCK34) Stock News, Headlines & Updates
Merck & Co Inc Stock News from GuruFocus
- 1
- 2
- 3
- 4
- 5
Jul 02, 2025
Merck (MRK) Faces Industry Turmoil Amid BIO's Rebuke of RFK Jr.
GuruFocus News • 2:56pm
Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer
Khac Phu Nguyen • 12:32pm
Merck (MRK) Seeks FDA Approval for Revised Winrevair Label
GuruFocus News • 6:56am
Merck & Co Inc (MRK) Announces FDA Priority Review for WINREVAIRâ„¢ Label Update | MRK stock news
GuruFocus News • 6:01am
FDA Grants Priority Review for WINREVAIRâ„¢ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial | MRK Stock News
GuruFocus News • 6:00am
FDA Grants Priority Review for WINREVAIRâ„¢ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
Business Wire • 6:00am
Jul 01, 2025
Merck & Co Inc (MRK) Shares Up 3.64% on Jul 1
GuruFocus News • 12:03pm
Merck & Co. (MRK) in Andrew Hill Investment Advisors 2023 Q1
GuruFocus News • 11:01am
Merck & Co Inc (MRK) Announces Second-Quarter 2025 Earnings Call | MRK stock news
GuruFocus News • 6:03am
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29 | MRK Stock News
GuruFocus News • 6:00am
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
Business Wire • 6:00am
Jun 27, 2025
Merck (MRK) in Carillon Eagle Growth & Income Fund 2024 Q1
GuruFocus News • 11:00am
Jun 26, 2025
Merck's (MRK) Enflonsia Gains CDC Panel's Backing for Infant RSV Protection | MRK Stock News
GuruFocus News • 1:00pm
ACIP Recommends Use of Merck's ENFLONSIAâ„¢ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or
GuruFocus News • 12:45pm
CDC Panel Endorses Merck's (MRK) Enflonsia for Infant RSV Protection
GuruFocus News • 8:58am
Jun 25, 2025
Merck (MRK) Eyes In Focus As CDC Panel Reviews Vaccine Recommendations
GuruFocus News • 7:56am
Jun 24, 2025
Merck & Co Inc (MRK) Announces Virtual Investor Event on HIV Research Pipeline | MRK stock news
GuruFocus News • 6:03am
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention | MRK Stock News
GuruFocus News • 6:00am
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
Business Wire • 6:00am
Jun 23, 2025
Merck (MRK) Announces Positive Phase 3 HYPERION Trial Results | MRK Stock News
GuruFocus News • 12:52pm
Merck (MRK) Hits Milestone with Winrevair PAH Therapy
GuruFocus News • 10:59am
Merck & Co Inc (MRK) Announces Positive Results from Phase 3 HYPERION Study for PAH Treatment | MRK stock news
GuruFocus News • 6:04am
Merck Announces Phase 3 HYPERION Study of WINREVAIRâ„¢ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH) | MRK Stock News
GuruFocus News • 6:01am
Merck Announces Phase 3 HYPERION Study of WINREVAIRâ„¢ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Business Wire • 6:00am
Jun 18, 2025
Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes
GuruFocus News • 2:57pm
MRK: Gardasil Dosing Proposal Absent from FDA Advisory Agenda | MRK Stock News
GuruFocus News • 1:15pm
Merck (MRK) Expands Deals with Chinese Pharma Companies
GuruFocus News • 12:55pm
Merck & Co Inc (MRK) Initiates Phase 3 Trial for Innovative Prostate Cancer Treatment | MRK stock news
GuruFocus News • 8:15am
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
Business Wire • 7:00am
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer | MRK Stock News
GuruFocus News • 6:18am
Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News
GuruFocus News • 6:17am
Jun 16, 2025
Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed
GuruFocus News • 9:57am
Jun 13, 2025
Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks
GuruFocus News • 2:56pm
FDA Approves Merck's Keytruda for Head and Neck Cancer
GuruFocus News • 7:57am
FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News
GuruFocus News • 6:15am
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy W
GuruFocus News • 6:00am
Jun 12, 2025
Merck (MRK) Awaits EU Approval for New Pet Medicine
GuruFocus News • 4:59pm
Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News
GuruFocus News • 4:16pm
Merck & Co Inc (MRK) Announces Positive EMA Opinion for NUMELVIâ„¢ Tablets for Dogs | MRK stock news
GuruFocus News • 4:01pm
- 1
- 2
- 3
- 4
- 5
Show
Entries
Headlines
Total 0- 1
No recent news